Quantitative Systematic Strategies LLC Sells 16,290 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Quantitative Systematic Strategies LLC trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 80.6% during the 2nd quarter, Holdings Channel reports. The firm owned 3,922 shares of the medical research company’s stock after selling 16,290 shares during the quarter. Quantitative Systematic Strategies LLC’s holdings in Charles River Laboratories International were worth $1,451,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Parkside Financial Bank & Trust lifted its position in Charles River Laboratories International by 6.6% during the second quarter. Parkside Financial Bank & Trust now owns 402 shares of the medical research company’s stock valued at $149,000 after buying an additional 25 shares during the period. Centerpoint Advisors LLC lifted its position in Charles River Laboratories International by 60.0% during the second quarter. Centerpoint Advisors LLC now owns 80 shares of the medical research company’s stock valued at $30,000 after buying an additional 30 shares during the period. Archer Investment Corp lifted its position in Charles River Laboratories International by 13.2% during the second quarter. Archer Investment Corp now owns 257 shares of the medical research company’s stock valued at $95,000 after buying an additional 30 shares during the period. Greenleaf Trust lifted its position in Charles River Laboratories International by 4.2% during the second quarter. Greenleaf Trust now owns 749 shares of the medical research company’s stock valued at $277,000 after buying an additional 30 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its position in Charles River Laboratories International by 2.4% during the second quarter. Oppenheimer & Co. Inc. now owns 1,462 shares of the medical research company’s stock valued at $541,000 after buying an additional 34 shares during the period. Institutional investors own 93.28% of the company’s stock.

Several brokerages have recently weighed in on CRL. JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $375.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, May 28th. Credit Suisse Group raised their price target on Charles River Laboratories International from $385.00 to $420.00 and gave the company a “neutral” rating in a report on Thursday, August 5th. raised their price target on Charles River Laboratories International from $350.00 to $355.00 and gave the company a “neutral” rating in a report on Friday, May 28th. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating and set a $458.00 price target for the company. in a report on Wednesday, September 15th. Finally, Citigroup raised their price target on Charles River Laboratories International from $350.00 to $355.00 and gave the company a “neutral” rating in a report on Friday, May 28th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Buy” and a consensus target price of $400.79.

In related news, CEO James C. Foster sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 6th. The stock was sold at an average price of $401.79, for a total value of $4,017,900.00. Following the transaction, the chief executive officer now directly owns 212,299 shares of the company’s stock, valued at approximately $85,299,615.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP William D. Barbo sold 12,387 shares of the business’s stock in a transaction that occurred on Friday, August 6th. The stock was sold at an average price of $402.82, for a total value of $4,989,731.34. Following the completion of the transaction, the vice president now directly owns 4,371 shares in the company, valued at $1,760,726.22. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,900 shares of company stock worth $16,673,320. Insiders own 1.20% of the company’s stock.

Shares of Charles River Laboratories International stock traded down $5.96 during trading hours on Monday, reaching $434.49. 2,813 shares of the stock traded hands, compared to its average volume of 421,106. Charles River Laboratories International, Inc. has a one year low of $205.97 and a one year high of $450.84. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $21.90 billion, a price-to-earnings ratio of 56.76, a P/E/G ratio of 3.07 and a beta of 1.14. The company has a 50 day moving average price of $416.78 and a 200 day moving average price of $357.87.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Tuesday, August 3rd. The medical research company reported $2.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.23. Charles River Laboratories International had a return on equity of 23.59% and a net margin of 12.10%. The firm had revenue of $914.61 million for the quarter, compared to analysts’ expectations of $880.72 million. During the same period in the previous year, the firm earned $1.58 EPS. The business’s quarterly revenue was up 34.0% on a year-over-year basis. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.25 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

Further Reading: Trading signals using Bollinger bands

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.